Lack of impact of therapy on extent of Barrett's esophagus in 67 patients - PubMed (original) (raw)
Lack of impact of therapy on extent of Barrett's esophagus in 67 patients
R E Sampliner et al. Dig Dis Sci. 1990 Jan.
Abstract
Sixty-seven patients with Barrett's esophagus have been prospectively followed over an average of 36 months (range 6 to 76 months) with standardized endoscopic observation and biopsies of the length of columnar epithelium. The initial length of Barrett's epithelium ranged from 1 to 16 cm, mean 5.5 cm. Specialized columnar epithelium was present in 64 of the 67 patients. Patients were treated predominantly with H2-receptor blocker therapy to relieve symptoms. Eighty-two percent of patients had less than a 1-cm change in length per year. The mean rate of change of length was -0.093 cm per year. These results confirm in a relatively large, prospective study that standard antireflux therapy for Barrett's esophagus does not result in consistent reduction in the extent of Barrett's epithelium over a three-year interval.
Similar articles
- Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE. Sampliner RE. Am J Gastroenterol. 1994 Oct;89(10):1844-8. Am J Gastroenterol. 1994. PMID: 7942680 Clinical Trial. - Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP, Badr AS, Hassanein RS. Weston AP, et al. Am J Gastroenterol. 1999 Dec;94(12):3420-6. doi: 10.1111/j.1572-0241.1999.01603.x. Am J Gastroenterol. 1999. PMID: 10606297 - Long term continuous omeprazole treatment of patients with Barrett's oesophagus.
Neumann CS, Iqbal TH, Cooper BT. Neumann CS, et al. Aliment Pharmacol Ther. 1995 Aug;9(4):451-4. doi: 10.1111/j.1365-2036.1995.tb00405.x. Aliment Pharmacol Ther. 1995. PMID: 8527623 Clinical Trial. - Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S, Rubenstein JH, Vieth M, Bergman J. Wani S, et al. Gastroenterology. 2016 Nov;151(5):822-835. doi: 10.1053/j.gastro.2016.09.040. Epub 2016 Oct 1. Gastroenterology. 2016. PMID: 27702561 Review. - Diagnosis and treatment of Barrett's oesophagus. A general survey.
Petrakis IE, Sciacca V, Iascone C. Petrakis IE, et al. Acta Chir Belg. 2001 Mar-Apr;101(2):53-8. Acta Chir Belg. 2001. PMID: 11396051 Review.
Cited by
- Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation.
Barham CP, Jones RL, Biddlestone LR, Hardwick RH, Shepherd NA, Barr H. Barham CP, et al. Gut. 1997 Sep;41(3):281-4. doi: 10.1136/gut.41.3.281. Gut. 1997. PMID: 9378378 Free PMC article. - Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.
Stein HJ, Siewert JR. Stein HJ, et al. Dysphagia. 1993;8(3):276-88. doi: 10.1007/BF01354551. Dysphagia. 1993. PMID: 8359051 Review. - Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls.
Hirschowitz BI. Hirschowitz BI. Dig Dis Sci. 1996 Jul;41(7):1384-91. doi: 10.1007/BF02088563. Dig Dis Sci. 1996. PMID: 8689915 - Regression of Barrett's esophagus by laser ablation in an anacid environment.
Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Sampliner RE, et al. Dig Dis Sci. 1993 Feb;38(2):365-8. doi: 10.1007/BF01307557. Dig Dis Sci. 1993. PMID: 8425450 - The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.
Chang EY, Morris CD, Seltman AK, O'Rourke RW, Chan BK, Hunter JG, Jobe BA. Chang EY, et al. Ann Surg. 2007 Jul;246(1):11-21. doi: 10.1097/01.sla.0000261459.10565.e9. Ann Surg. 2007. PMID: 17592284 Free PMC article. Review.
References
- Am J Gastroenterol. 1986 Sep;81(9):764-6 - PubMed
- J Clin Gastroenterol. 1987 Apr;9(2):139-41 - PubMed
- Gastroenterology. 1984 Oct;87(4):927-33 - PubMed
- Am J Gastroenterol. 1988 Sep;83(9):914-6 - PubMed
- N Engl J Med. 1986 Aug 7;315(6):362-71 - PubMed